FPI-1966 by Fusion Pharmaceuticals for Solid Tumor: Likelihood of Approval

FPI-1966 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FPI-1966’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FPI-1966 overview

FPI-1966 is under development for the treatment of solid tumor, head and neck cancer squamous cell carcinoma and bladder carcinoma. The drug candidate comprises of alpha particle emitting isotope actinium-225 is conjugated with targeting molecule. It acts by targeting cells expressing fibroblast growth factor receptor 3 (FGFR3). It is developed based on the Fast-Clear Linker technology.

Fusion Pharmaceuticals overview

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company which develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059 and FPI-1966. The company’s pipeline products are to treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. Fusion Pharmaceuticals carters its products under brand Keytruda. The company is a spin-off from the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre in Canada. It has its operations in the US and Canada. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada.

For a complete picture of FPI-1966’s drug-specific PTSR and LoA scores, buy the report here.